AQST Aquestive Therapeutics, Inc.

NASDAQ
$4.44

Aquestive Therapeutics, Inc. (AQST) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran below AQST's own trailing one-year pace, with 27% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 2 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
2
2 transactions
Purchases
$0
0 shares
Sales
$166.2K
33,750 shares
Net activity
-$166.2K
purchases less sales

How much of that selling was preplanned? 27% planned / 73% discretionary

10b5-1 plan sales $45.7K 1 transaction · 8,750 shares
Discretionary sales $120.5K 1 transaction · 25,000 shares

Largest single sale: $120.5K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Barber Daniel President and CEO Sell 25,000 $4.82 $120.5K 652,317 −3.7% of holding
Korczynski Sherry Chief Commercial Officer Sell 10b5-1 8,750 $5.22 $45.7K 235,689 −3.6% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.